This HTML5 document contains 58 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n8http://localhost/temp/predkladatel/
n9http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n10http://linked.opendata.cz/ontology/domain/vavai/
n5http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11130%2F09%3A5715%21RIV10-MZ0-11130___/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n13http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11130%2F09%3A5715%21RIV10-MZ0-11130___
rdf:type
n10:Vysledek skos:Concept
dcterms:description
Distinction between grade II ependymomas and anaplastic ependymomas based on histopathological examination solely is problematic. Therefore, we performed systematic review (SR) and meta-analysis (MA) of data published on immunohistochemical prognostic markers (IPM) in intracranial ependymomas (IE) in order to establish an evidence-based perspective on their clinical value. 30 studies reporting results on IPM in IE were identified. Due to a pronounced inter-study heterogeneity, only 14 publications fulfilled the criteria for inclusion into SR. From the total of 67 immunohistochemical markers, 18 were found to correlate with prognosis. However, due to inadequate data publishing, MA could be performed only with data on proliferation marker MIB-1 (Ki-67) from 5 publications, including 337 patients: The pooled hazard ratio for overall survival was 3.16 (95% confidence interval = 1.96 – 5.09; p < 0.001) implicating that patients with tumors with higher expression of MIB-1 had a significantly worse outcome. Distinction between grade II ependymomas and anaplastic ependymomas based on histopathological examination solely is problematic. Therefore, we performed systematic review (SR) and meta-analysis (MA) of data published on immunohistochemical prognostic markers (IPM) in intracranial ependymomas (IE) in order to establish an evidence-based perspective on their clinical value. 30 studies reporting results on IPM in IE were identified. Due to a pronounced inter-study heterogeneity, only 14 publications fulfilled the criteria for inclusion into SR. From the total of 67 immunohistochemical markers, 18 were found to correlate with prognosis. However, due to inadequate data publishing, MA could be performed only with data on proliferation marker MIB-1 (Ki-67) from 5 publications, including 337 patients: The pooled hazard ratio for overall survival was 3.16 (95% confidence interval = 1.96 – 5.09; p < 0.001) implicating that patients with tumors with higher expression of MIB-1 had a significantly worse outcome.
dcterms:title
Immunohistochemical Prognostic Markers in Intracranial Ependymomas: Systematic Review and Meta-Analysis Immunohistochemical Prognostic Markers in Intracranial Ependymomas: Systematic Review and Meta-Analysis
skos:prefLabel
Immunohistochemical Prognostic Markers in Intracranial Ependymomas: Systematic Review and Meta-Analysis Immunohistochemical Prognostic Markers in Intracranial Ependymomas: Systematic Review and Meta-Analysis
skos:notation
RIV/00216208:11130/09:5715!RIV10-MZ0-11130___
n3:aktivita
n11:Z
n3:aktivity
Z(MSM0021620812), Z(MZ0FNM2005)
n3:cisloPeriodika
4
n3:dodaniDat
n13:2010
n3:domaciTvurceVysledku
n9:1987135 n9:7014457 n9:3100979 n9:7359551
n3:druhVysledku
n15:J
n3:duvernostUdaju
n14:S
n3:entitaPredkladatele
n16:predkladatel
n3:idSjednocenehoVysledku
318556
n3:idVysledku
RIV/00216208:11130/09:5715
n3:jazykVysledku
n17:eng
n3:klicovaSlova
Ependymoma; Immunohistochemistry; Ki-67; Meta-analysis; MIB-1; prognosis; ki-67 immunolabeling index; central-nervous-system; epithelial differentiation; cell-proliferation; labeling index; expression; survival; childhood; tumors; children
n3:klicoveSlovo
n4:children n4:tumors n4:central-nervous-system n4:cell-proliferation n4:Immunohistochemistry n4:epithelial%20differentiation n4:ki-67%20immunolabeling%20index n4:MIB-1 n4:labeling%20index n4:prognosis n4:Ki-67 n4:childhood n4:expression n4:survival n4:Ependymoma n4:Meta-analysis
n3:kodStatuVydavatele
HU - Maďarsko
n3:kontrolniKodProRIV
[4967C3882D9C]
n3:nazevZdroje
Pathology & Oncology Research
n3:obor
n18:FH
n3:pocetDomacichTvurcuVysledku
4
n3:pocetTvurcuVysledku
4
n3:rokUplatneniVysledku
n13:2009
n3:svazekPeriodika
15
n3:tvurceVysledku
Janda, Aleš Zámečník, Josef Kuncová, Klára Kasal, Pavel
n3:wos
000273283100009
n3:zamer
n5:MZ0FNM2005 n5:MSM0021620812
s:issn
1219-4956
s:numberOfPages
10
n8:organizacniJednotka
11130